title: Myelodysplastic syndrome.
authors.affiliation: Division of Medical Oncology and Hematology, Odette Cancer Centre (Wells, Buckstein); Department of Family Medicine (Rezmovitz), Sunnybrook Health Sciences Centre, Toronto, Ont. richard.wells@sunnybrook.ca.
authors.forename: Richard A
authors.initials: RA
authors.lastname: Wells
authors.affiliation: Division of Medical Oncology and Hematology, Odette Cancer Centre (Wells, Buckstein); Department of Family Medicine (Rezmovitz), Sunnybrook Health Sciences Centre, Toronto, Ont.
authors.forename: Rena
authors.initials: R
authors.lastname: Buckstein
authors.affiliation: Division of Medical Oncology and Hematology, Odette Cancer Centre (Wells, Buckstein); Department of Family Medicine (Rezmovitz), Sunnybrook Health Sciences Centre, Toronto, Ont.
authors.forename: Jeremy
authors.initials: J
authors.lastname: Rezmovitz
mesh_terms: D000368:Aged; D000748:Anemia, Macrocytic / Q000150:complications*; D001853:Bone Marrow / Q000473:pathology*; D004921:Erythropoietin / Q000008:administration & dosage; D005221:Fatigue; D006801:Humans; D000077269:Lenalidomide; D009190:Myelodysplastic Syndromes / Q000175:diagnosis* / Q000453:epidemiology* / Q000628:therapy; D033581:Stem Cell Transplantation; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D004921:Erythropoietin; D013792:Thalidomide; D000077269:Lenalidomide